van Solinge TS, Nieland L, Chiocca EA, Broekman MLD. Advances in native remedy for glioblastoma – taking the struggle to the tumour. Nat Rev Neurol. 2022;18:221–36.
Tan A, Ashley D, López G, Malinzak M, Friedman H. Khasraw MJCacjfc. Administration of glioblastoma: State-of-the-art and future instructions. 2020;70:299–312.
Brown T, Brennan M, Li M, Church E, Brandmeir N, Rakszawski Okay, Patel A, Rizk E, Suki D, Sawaya R, Glantz MJJo. Affiliation of the extent of Resection with Survival in Glioblastoma: a scientific overview and Meta-analysis. 2016;2:1460–9.
He J, Xiong X, Yang H, Li D, Liu X, Li S, Liao S, Chen S, Wen X, Yu Okay et al. Outlined tumor antigen-specific T cells potentiate personalised TCR-T cell remedy and prediction of immunotherapy response. 2022;32:530–42.
Leko V, Rosenberg SJCc. Figuring out and focusing on human tumor antigens for T cell-based immunotherapy of strong tumors. 2020;38:454–72.
Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E, Veerman Okay, Bettini S, Lafouresse F, Vina E et al. Tumor-associated excessive endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 mixture immunotherapy. 2022;40:318–334e319.
Whiteside TL. Exosome and mesenchymal stem cell cross-talk within the tumor microenvironment. Semin Immunol. 2018;35:69–79.
Tu Z, Karnoub AE. Mesenchymal stem/stromal cells in breast most cancers growth and administration. Semin Most cancers Biol. 2022;86:81–92.
Shi Y, Wang Y, Li Q, Liu Okay, Hou J, Shao C, Wang YJNrN. Immunoregulatory Mech mesenchymal stem stromal cells Inflamm Dis. 2018;14:493–507.
Wang Y, Chen X, Cao W, Shi, YJNi. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. 2014;15:1009–16.
Shahar T, Rozovski U, Hess Okay, Hossain A, Gumin J, Gao F, Fuller G, Goodman L, Sulman E. Lang FJN-o. share of mesenchymal stem cells in high-grade glioma tumor samples correlates with affected person survival. 2017;19:660–8.
Qi Y, Jin C, Qiu W, Zhao R, Wang S, Li B, Zhang Z, Guo Q, Zhang S, Gao Z et al. The twin position of glioma exosomal microRNAs: glioma eliminates tumor suppressor mir-1298-5p by way of exosomes to advertise immunosuppressive results of MDSCs. 2022;13:426.
Mi Y, Guo N, Luan J, Cheng J, Hu Z, Jiang P, Jin W, Gao X. The rising position of myeloid-derived suppressor cells within the Glioma Immune Suppressive Microenvironment. Entrance Immunol. 2020;11:737.
Bayik D, Zhou Y, Park C, Hong C, Vail D, Silver DJ, Lauko A, Roversi G, Watson DC, Lo A, et al. Myeloid-derived suppressor cell subsets drive Glioblastoma Development in a sex-specific method. Most cancers Discov. 2020;10:1210–25.
Hegde S, Chief AM, Merad M. MDSC: markers, growth, states, and unaddressed complexity. Immunity. 2021;54:875–84.
Del Montalbán I, Penski C, Schlahsa L, Stein RG, Diessner J, Wöckel A, Dietl J, Lutz MB, Mittelbronn M, Wischhusen J, Häusler SFM. Adenosine-generating ovarian most cancers cells entice myeloid cells which differentiate into adenosine-generating tumor related macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J Immunother Most cancers. 2016;4:49.
Zhang Y, Qu D, Solar J, Zhao L, Wang Q, Shao Q, Kong B, Zhang Y, Qu X. Human trophoblast cells induced MDSCs from peripheral blood CD14(+) myelomonocytic cells by way of elevated ranges of CCL2. Cell Mol Immunol. 2016;13:615–27.
Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger Okay, Khan M, Kuppusamy P, Guenterberg Okay, Kondadasula SV, Chaudhury AR, La Perle KM, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Most cancers Res. 2011;71:5101–10.
Di Virgilio F. Purines, purinergic receptors, and most cancers. Most cancers Res. 2012;72:5441–7.
Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and irritation. Developments Mol Med. 2013;19:355–67.
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji Okay, Linden J, Oukka M, et al. Adenosine era catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257–65.
Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody remedy inhibits breast tumor progress and metastasis. Proc Natl Acad Sci U S A. 2010;107:1547–52.
Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G. Anti-CD73 in most cancers immunotherapy: awakening new alternatives. Developments Most cancers. 2016;2:95–109.
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, et al. COAST: an Open-Label, section II, Multidrug platform research of Durvalumab alone or in Mixture with Oleclumab or Monalizumab in sufferers with Unresectable, Stage III Non-Small-Cell Lung Most cancers. J Clin Oncol. 2022;40:3383–93.
Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, et al. Immune profiling of human tumors identifies CD73 as a combinatorial goal in glioblastoma. Nat Med. 2020;26:39–46.
Han QF, Li WJ, Hu KS, Gao J, Zhai WL, Yang JH, Zhang SJ. Exosome biogenesis: equipment, regulation, and therapeutic implications in most cancers. Mol Most cancers. 2022;21:207.
Wu Y, Li J, Zeng Y, Pu W, Mu X, Solar Okay, Peng Y, Shen B. Exosomes rewire the cartilage microenvironment in osteoarthritis: from intercellular communication to therapeutic methods. Int J Oral Sci. 2022;14:40.
Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, Zhang S, Zhao S, Xu H, Li M, et al. EWSR1-induced circNEIL3 promotes glioma development and exosome-mediated macrophage immunosuppressive polarization by way of stabilizing IGF2BP3. Mol Most cancers. 2022;21:16.
Qiu W, Guo X, Li B, Wang J, Qi Y, Chen Z, Zhao R, Deng L, Qian M, Wang S, et al. Exosomal miR-1246 from glioma affected person physique fluids drives the differentiation and activation of myeloid-derived suppressor cells. Mol Ther. 2021;29:3449–64.
Qi Y, Jin C, Qiu W, Zhao R, Wang S, Li B, Zhang Z, Guo Q, Zhang S, Gao Z, et al. The twin position of glioma exosomal microRNAs: glioma eliminates tumor suppressor mir-1298-5p by way of exosomes to advertise immunosuppressive results of MDSCs. Cell Demise Dis. 2022;13:426.
Li C, Ni Y, Xu H, Xiang Q, Zhao Y, Zhan J, He J, Li S. Liu YJSt, remedy t. roles and mechanisms of exosomal non-coding RNAs. Hum well being Dis. 2021;6:383.
Witwer KW, Soekmadji C, Hill AF, Wauben MH, Buzás EI, Di Vizio D, Falcon-Perez JM, Gardiner C, Hochberg F, Kurochkin IV, et al. Updating the MISEV minimal necessities for extracellular vesicle research: constructing bridges to reproducibility. J Extracell Vesicles. 2017;6:1396823.
Ambros V. microRNAs: tiny regulators with nice potential. Cell. 2001;107:823–6.
Zheng D, Huo M, Li B, Wang W, Piao H, Wang Y, Zhu Z, Li D, Wang T, Liu Okay. The position of Exosomes and Exosomal MicroRNA in Cardiovascular Illness. Entrance Cell Dev Biol. 2020;8:616161.
Guo X, Qiu W, Liu Q, Qian M, Wang S, Zhang Z, Gao X, Chen Z, Xue H, Li G. Immunosuppressive results of hypoxia-induced glioma exosomes by means of myeloid-derived suppressor cells by way of the miR-10a/Rora and miR-21/Pten pathways. Oncogene. 2018;37:4239–59.
Li B, Chen X, Qiu W, Zhao R, Duan J, Zhang S, Pan Z, Zhao S, Guo Q, Qi Y, et al. Synchronous disintegration of Ferroptosis Protection Axis by way of Engineered Exosome-Conjugated magnetic nanoparticles for Glioblastoma Remedy. Adv Sci (Weinh). 2022;9:e2105451.
Liu L, Li Y, Peng H, Liu R, Ji W, Shi Z, Shen J, Ma G, Zhang X. Focused exosome coating gene-chem nanocomplex as “nanoscavenger” for clearing alpha-synuclein and immune activation of Parkinson’s illness. Sci Adv 2020;6.
Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-Induced discount of CD39 and CD73 blocks myeloid-derived suppressor cell exercise in sufferers with ovarian Most cancers. Most cancers Res. 2018;78:1779–91.
Quezada C, Torres Á, Niechi I, Uribe D, Contreras-Duarte S, Toledo F, San Martín R, Gutiérrez J, Sobrevia L. Function of extracellular vesicles in glioma development. Mol Elements Med. 2018;60:38–51.
Lin Y, Zhang C, Xiang P, Shen J, Solar W, Yu H. Exosomes derived from HeLa cells break down vascular integrity by triggering endoplasmic reticulum stress in endothelial cells. J Extracell Vesicles. 2020;9:1722385.
Hirota SA, Fines Okay, Ng J, Traboulsi D, Lee J, Ihara E, Li Y, Willmore WG, Chung D, Scully MM, et al. Hypoxia-inducible issue signaling offers safety in Clostridium difficile-induced intestinal damage. Gastroenterology. 2010;139:259–269e253.
Cheng S, Quintin J, Cramer R, Shepardson Okay, Saeed S, Kumar V, Giamarellos-Bourboulis E, Martens J, Rao N, Aghajanirefah A et al. mTOR- and HIF-1α-mediated cardio glycolysis as metabolic foundation for skilled immunity. 2014;345:1250684.
Shafee N, Kaluz S, Ru N, Stanbridge EJCl. PI3K/Akt exercise has variable cell-specific results on expression of HIF goal genes, CA9 and VEGF, in human most cancers cell traces. 2009;282:109–15.
Yoshida H, Matsui T, Yamamoto A, Okada T, Mori Okay. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to supply a extremely energetic transcription issue. Cell. 2001;107:881–91.
Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, Gao F, Narain NR, DiFiglia M, Kiebish MA, et al. Excessive-resolution proteomic and lipidomic evaluation of exosomes and microvesicles from totally different cell sources. J Extracell Vesicles. 2016;5:32570.
Zhang Okay, Kaufman RJ. The unfolded protein response: a stress signaling pathway important for well being and illness. Neurology. 2006;66:102–9.
Zhou W, Xu Y, Zhang J, Zhang P, Yao Z, Yan Z, Wang H, Chu J, Yao S, Zhao S, et al. MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA harm restore in diffuse massive B-cell lymphoma. Leukemia. 2022;36:1861–9.
Zhang Q, Wang HY, Liu X, Bhutani G, Kantekure Okay, Wasik M. IL-2R frequent gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by focusing on NPM-ALK. Proc Natl Acad Sci U S A. 2011;108:11977–82.
Kishikawa S, Murata T, Kimura H, Shiota Okay, Yokoyama KK. Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. Eur J Biochem. 2002;269:2961–70.
Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, Wang YC. Dysregulation of p53/Sp1 management results in DNA methyltransferase-1 overexpression in lung most cancers. Most cancers Res. 2010;70:5807–17.
Alptekin A, Parvin M, Chowdhury H, Rashid M. Arbab AJIr. Engineered exosomes for research in tumor immunology. 2022;312:76–102.
Rehman FU, Liu Y, Zheng M, Shi B. Exosomes based mostly methods for mind drug supply. Biomaterials. 2023;293:121949.
Allard B, Pommey S, Smyth MJ, Stagg J. Concentrating on CD73 enhances the antitumor exercise of anti-PD-1 and anti-CTLA-4 mAbs. Clin Most cancers Res. 2013;19:5626–35.
Houlihan DD, Mabuchi Y, Morikawa S, Niibe Okay, Araki D, Suzuki S, Okano H, Matsuzaki Y. Isolation of mouse mesenchymal stem cells on the idea of expression of Sca-1 and PDGFR-alpha. Nat Protoc. 2012;7:2103–11.
Morikawa S, Mabuchi Y, Kubota Y, Nagai Y, Niibe Okay, Hiratsu E, Suzuki S, Miyauchi-Hara C, Nagoshi N, Sunabori T, et al. Potential identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med. 2009;206:2483–96.
Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, Yuan ZR, Roberts AI, Zhang L, Zheng B, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor growth and is mimicked by TNFalpha. Cell Stem Cell. 2012;11:812–24.
Sampson JH, Gunn MD, Fecci PE, Ashley DM. Mind immunology and immunotherapy in mind tumours. Nat Rev Most cancers. 2020;20:12–25.
Takacs GP, Flores-Toro JA, Harrison JK. Modulation of the chemokine/chemokine receptor axis as a novel method for glioma remedy. Pharmacol Ther. 2021;222:107790.
Nowak B, Rogujski P, Janowski M, Lukomska B, Andrzejewska A. Mesenchymal stem cells in glioblastoma remedy and development: how one cell does all of it. Biochim Biophys Acta Rev Most cancers. 2021;1876:188582.
Figueroa J, Phillips LM, Shahar T, Hossain A, Gumin J, Kim H, Bean AJ, Calin GA, Fueyo J, Walters ET, et al. Exosomes from Glioma-Related Mesenchymal stem cells enhance the tumorigenicity of glioma stem-like cells by way of switch of miR-1587. Most cancers Res. 2017;77:5808–19.
Takayama Y, Kusamori Okay, Nishikawa M. Mesenchymal stem/stromal cells as next-generation drug supply automobiles for most cancers therapeutics. Knowledgeable Opin Drug Deliv. 2021;18:1627–42.
Pacioni S, D’Alessandris QG, Giannetti S, Morgante L, De Pascalis I, Cocce V, Bonomi A, Pascucci L, Alessandri G, Pessina A, et al. Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic harm in glioblastoma mind xenografts. Stem Cell Res Ther. 2015;6:194.
Allahverdi A, Arefian E, Soleimani M, Ai J, Nahanmoghaddam N, Yousefi-Ahmadipour A, Ebrahimi-Barough S. MicroRNA-4731-5p delivered by AD-mesenchymal stem cells induces cell cycle arrest and apoptosis in glioblastoma. J Cell Physiol. 2020;235:8167–75.
Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, Bobbitt Okay, Rempel SA, Hasselbach L, Mikkelsen T, et al. Mesenchymal stem cells ship artificial microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4:346–61.
Mohme M, Maire CL, Geumann U, Schliffke S, Duhrsen L, Fita Okay, Akyuz N, Binder M, Westphal M, Guenther C, et al. Native Intracerebral Immunomodulation utilizing interleukin-expressing mesenchymal stem cells in Glioblastoma. Clin Most cancers Res. 2020;26:2626–39.
Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER, et al. Mesenchymal stem cells efficiently ship oncolytic virotherapy to diffuse intrinsic pontine glioma. Clin Most cancers Res. 2021;27:1766–77.
Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, et al. Mesenchymal stem cells remoted from human gliomas enhance proliferation and keep stemness of glioma stem cells by means of the IL-6/gp130/STAT3 pathway. Stem Cells. 2015;33:2400–15.
Zhang Q, Yi DY, Xue BZ, Wen WW, Lu YP, Abdelmaksou A, Solar MX, Yuan DT, Zhao HY, Xiong NX, et al. CD90 decided two subpopulations of glioma-associated mesenchymal stem cells with totally different roles in tumour development. Cell Demise Dis. 2018;9:1101.
Ghasempour E, Hesami S, Movahed E, Keshel SH, Doroudian M. Mesenchymal stem cell-derived exosomes as a brand new therapeutic technique within the mind tumors. Stem Cell Res Ther. 2022;13:527.
Wang M, Xin Y, Cao H, Li W, Hua Y, Webster TJ, Zhang C, Tang W, Liu Z. Latest advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug supply. Biomater Sci. 2021;9:1088–103.
Mensa E, Guescini M, Giuliani A, Bacalini MG, Ramini D, Corleone G, Ferracin M, Fulgenzi G, Graciotti L, Prattichizzo F, et al. Small extracellular vesicles ship miR-21 and miR-217 as pro-senescence effectors to endothelial cells. J Extracell Vesicles. 2020;9:1725285.
Jung BK, Track H, Shin H, Chai JY. Exosomal miRNA-21 from Toxoplasma gondii-infected microglial cells induces the expansion of U87 glioma cells by inhibiting tumor suppressor genes. Sci Rep. 2022;12:16450.
Lan F, Pan Q, Yu H, Yue X. Sulforaphane enhances temozolomide-induced apoptosis due to down-regulation of miR-21 by way of Wnt/β-catenin signaling in glioblastoma. J Neurochem. 2015;134:811–8.
Griveau A, Bejaud J, Anthiya S, Avril S, Autret D, Garcion E. Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell dying. Int J Pharm. 2013;454:765–74.
Anthiya S, Griveau A, Loussouarn C, Baril P, Garnett M, Issartel JP, Garcion E. MicroRNA-Based mostly medicine for mind tumors. Developments Most cancers. 2018;4:222–38.
Armstrong JP, Holme MN, Stevens MM. Re-engineering extracellular vesicles as sensible Nanoscale therapeutics. ACS Nano. 2017;11:69–83.
van Niel G, D’Angelo G, Raposo G. Shedding gentle on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213–28.
Xia J, Miao Y, Wang X, Huang X, Dai J. Latest progress of dendritic cell-derived exosomes (dex) as an anti-cancer nanovaccine. Biomed Pharmacother. 2022;152:113250.
Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, et al. Vaccination of metastatic melanoma sufferers with autologous dendritic cell (DC) derived-exosomes: outcomes of thefirst section I medical trial. J Transl Med. 2005;3:10.
Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, et al. A section I research of dexosome immunotherapy in sufferers with superior non-small cell lung most cancers. J Transl Med. 2005;3:9.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, et al. Dendritic cell-derived exosomes as upkeep immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5:e1071008.
Pitt JM, Andre F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for most cancers remedy. J Clin Make investments. 2016;126:1224–32.
Gu X, Erb U, Buchler MW, Zoller M. Improved vaccine efficacy of tumor exosome in comparison with tumor lysate loaded dendritic cells in mice. Int J Most cancers. 2015;136:E74–84.
Du L, Lee JH, Jiang H, Wang C, Wang S, Zheng Z, Shao F, Xu D, Xia Y, Li J et al. beta-catenin induces transcriptional expression of PD-L1 to advertise glioblastoma immune evasion. J Exp Med 2020;217.
Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, et al. OS10.3 Randomized section 3 research evaluating the efficacy and security of Nivolumab vs Bevacizumab in sufferers with recurrent glioblastoma: CheckMate 143. Neurooncology. 2017;19:iii21–1.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bahr O, et al. Impact of Nivolumab vs Bevacizumab in sufferers with recurrent glioblastoma: the CheckMate 143 section 3 Randomized Scientific Trial. JAMA Oncol. 2020;6:1003–10.
Flores-Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF, Singh R, Schall TJ, Datta M, Jain RK, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor impact to gradual development of resistant murine gliomas. Proc Natl Acad Sci U S A. 2020;117:1129–38.